HIGHLIGHT
MenQuadfi

MenQuadfi

vaccine, meningococcal

Manufacturer:

sanofi pasteur

Distributor:

DKSH
Concise Prescribing Info
Contents
Meningococcal group A, C, W & Y conjugate vaccine
Indications/Uses
Active immunisation of individuals ≥12 mth against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W & Y.
Dosage/Direction for Use
IM Primary vaccination Individual ≥12 mth 0.5 mL single dose. Booster vaccination Individual who previously received meningococcal vaccine containing the same serogroups 0.5 mL single dose.
Contraindications
Special Precautions
Appropriate medical treatment & supervision should be readily available in case of anaphylactic event following vaccination. Not to be administered SC, intravascularly or intradermally. Postpone vaccination in individuals suffering from acute severe febrile illness. Possible syncope & other anxiety-related reactions following or even before vaccination as psychogenic response to needle inj; place procedures to prevent falling or injury. Individuals w/ thrombocytopenia or any coagulation disorder. No protection against any other Neisseria meningitidis groups; may not protect all vaccine recipients. Individuals at high risk for MenA infection who received MenC-CRM vaccine in their 1st yr of life. Adequate immune response may not be elicited in patients receiving immunosuppressive treatment or those w/ immunodeficiency. Not a substitute for routine tetanus immunisation. Contains Na <1 mmol/dose. Some adverse effects may temporarily affect ability to drive or use machines. Pregnancy & lactation. Paed <12 mth.
Adverse Reactions
Inj site tenderness/pain. Inj site swelling & erythema; fever. Individual ≥2 yr: Headache; myalgia; malaise. Individual 12-23 mth: Appetite loss; irritability; drowsiness; abnormal crying. Vomiting, diarrhoea.
Drug Interactions
Consider separate administration of MenQuadfi & 13-valent pneumococcal polysaccharide conjugated vaccine in childn 12-23 mth at high risk for serogroup A disease. Administer concomitant vaccines at separate inj sites preferably contralateral. Adequate immune response may not be elicited in patients receiving immunosuppressive treatment.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AH - Meningococcal vaccines ; Used for active immunizations.
Presentation/Packing
Form
MenQuadfi soln for inj 0.5 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in